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Abstract
Background: IL6-related T cell activation and TNFα-dependent cell proliferation are major targets of therapy in the
RA synovium. We investigated whether expression of these pathways in RA synovial biopsies is associated with
disease activity and response to therapy.
Method: Correlation and gene set enrichment studies were performed using gene expression profiles from RA
synovial biopsies. Immunostaining experiments of GADD45B and PDE4D were performed on independent
additional sets of early untreated RA samples, obtained in two different centers by needle-arthroscopy or US-guided
biopsies.
Results: In 65 RA synovial biopsies, transcripts correlating with disease activity were strongly enriched in TNFα-
induced genes. Out of the individual variables used in disease-activity scores, tender joint count, swollen joint count
and physician’s global assessment, but not CRP or patient’s global assessment displayed a similar correlation with
the expression of TNFα-dependent genes. In addition, TNFα-induced genes were also significantly enriched in
transcripts over-expressed in synovial biopsy samples obtained from poor-responders to methotrexate or
tocilizumab, prior to initiation of therapy.
GADD45B (induced by TNFα in monocytes) and PDE4D (induced by TNFα in FLS) immunostaining was significantly
higher in overall poor-responders to therapy in 46 independent baseline samples obtained from early untreated RA
patients prior to initiation of therapy. GADD45B (but not PDE4D) immunostaining was significantly higher in the
sub-group of patients with poor-response to methotrexate therapy, and this was confirmed in another population
of methotrexate-treated patients.
Conclusion: Higher expression of TNFα-induced transcripts in early RA synovitis is associated with higher disease
activity, and predicts poor response to first-line therapy. That over-expression of TNFα-induced genes predicts poor-
response to therapy regardless of the drug administered, indicates that this molecular signature is associated with
disease severity, rather than with specific pathways of escape to therapy.
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Background
Access to synovial material from patients with rheuma-
toid arthritis (RA) provides unique opportunities to in-
vestigate local molecular and cellular mechanisms of
inflammation, and their links with clinical outcomes.
Thus, histological and gene expression studies on RA
synovial biopsies recently showed the presence of dis-
tinct, although partly overlapping, phenotypes: myeloid,
lymphoid, low inflammatory and fibroid, based on most
prevalent cell type, and related gene expression patterns.
Concentrations of serum markers associated with these
phenotypes were found to be informative about response
to therapy in a biomarker study performed in patients
included in the ADACTA trial. Thus, a high baseline
serum sICAM1/CXCL13 ratio, reflecting a myeloid
phenotype, predicted a higher probability of response to
TNF blockade (American College of Rheumatology 50 %
response (ACR50) 42 % versus 13 %), while a high
CXCL13/sICAM1 ratio (lymphoid phenotype) was rather
associated with better response rates to tocilizumab
therapy (ACR50 69 % versus 20 %) [1, 2].
Using high-density and customized low-density gene
expression platforms, we also found heterogeneous ex-
pression of T cell (lymphoid)-associated transcripts in
RA synovial tissue. In a group of 32 biopsies obtained in
treated and untreated patients, we observed that expres-
sion of these transcripts displayed a significant, albeit
moderate (0.40 < r <0.55) correlation with disease activ-
ity (disease activity score in 28 joints-C reactive protein
(DAS28-CRP)) [3, 4]. In other studies, we evaluated the
effects of therapies on global gene expression patterns in
prospective synovial biopsy samples obtained prior to
and 3 months after initiation of therapy with methotrex-
ate, tocilizumab, rituximab or adalimumab. We showed
that methotrexate, tocilizumab and rituximab display
very similar molecular effects in RA synovitis, character-
ized by a decrease in T cell activation genes [5, 6]. By
contrast, TNF blockade resulted in a decrease in the ex-
pression of transcripts involved in cell proliferation and
inflammation. Interestingly, higher baseline expression of
TNFα-induced transcripts in RA synovial tissue was asso-
ciated with decreased responses to TNF blockade in
methotrexate-resistant patients [7, 8]. These observations
probably indicate that, in some cases, tissue impregnation
in TNFα is too high to be blocked using standard TNF
blockade regimens.
Overall, these observations indicate that expression of
TNFα- or T cell-associated transcripts displays a large
level of plasticity in RA synovitis, related to disease ac-
tivity, and effects of therapy. We therefore undertook
the present study, on existing sets of gene expression
data generated in our laboratory, in order to investigate
the impact of disease activity on synovial molecular
pathways, and assess whether variations in synovial gene
expression profiles are also informative about disease
outcomes.
Methods
Gene expression data sets
Transcriptomic data (GeneChip Human Genome U133
Plus2.0.CEL files, Affymetrix) from 65 samples ob-
tained by needle-arthroscopic knee synovial biopsy
were used in the present analyses. These samples were
obtained in untreated RA patients (<1 year disease dur-
ation for the majority of them), prior to and 3 months
after initiation of tocilizumab (n = 13 and 12 samples, re-
spectively) or methotrexate (n = 2 × 8 samples) therapy
[GEO:GSE45867] (National Center for Biotechnology
Information; http://www.ncbi.nlm.nih.gov/geo), and in RA
patients resistant to TNF blockade, prior to and
3 months after administration of rituximab (n = 2 × 12
samples, GSE24742) therapy [5, 6]. All patients met the
ACR/European League Against Rheumatism (EULAR)
2010 RA classification criteria, and the ACR 1987 re-
vised classification for RA. Patients’ characteristics are
displayed in Table 1.
Student’s t tests, correlation and pathway analyses
Selected .CEL files were uploaded on GeneSpring soft-
ware (Agilent Technologies), and fluorescence intensity
data were normalized using robust multi-array analysis.
Normalized, log2-transformed gene expression data
were exported on Excel (Microsoft) in order to calculate
Pearson r correlation coefficients with disease activity
score in 28 joints using the C-reactive protein level
(DAS28-CRP), simplified disease activity index (SDAI),
clinical disease activity index (CDAI) or each individual
component of these scores. Student’s t test (without cor-
rection for multiple comparisons) was performed on
baseline gene expression data from good versus poor re-
sponders to therapy, using GeneSpring. A cutoff value
of 1.5 was further used to discriminate genes over-
expressed in poor versus good responders to therapy.
Pathway analyses were performed with lists of probe
sets displaying a Pearson r correlation coefficient >0.5
with DAS28-CRP, using the Database for Annotation,
Visualization and Integrated Discovery (DAVID), an ap-
plication that interrogates functional annotation data-
bases (Gene Ontology, KEGG, Biocarta and InterPro),
and finds overrepresented biologic themes within a
group of genes (http://david.abcc.ncifcrf.gov) [9].
Gene set enrichment analyses
Lists of selected probe sets were uploaded on GeneSpring,
and their eigenvalues were calculated in several experi-
ments. Eigenvalues are the percentages of variation in gene
expression data that are explained by the principal compo-
nent of the experiment (whatever the amplitude of the
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variation). The influence of IL6 was assessed using synovial
biopsy samples prior to and after administration of toci-
lizumab, an anti-IL6R antibody, using GSE45867 data. The
effects of TNFα were analyzed using online available
gene expression data (GSE38351) obtained from mono-
cytes (n = 3) cultured for 1.5 hours in the presence or
the absence of TNFα [10], and gene expression data
produced in our laboratory on synovial fibroblast-like
synoviocytes (FLS) cultured overnight in the presence
or the absence of TNFα (10 ng/ml). For this experiment,
FLS were purified from synovial biopsies from one pa-
tient with osteoarthritis, and two patients with RA, as
previously described [8]. After overnight incubation,
cells were detached and total RNA was extracted using
the Nucleospin RNA II extraction kit (Macherey-Nagel),
including DNase treatment of the samples. Comple-
mentary RNA (cRNA) was synthetized, biotin-labeled
and fragmented according to a standard Affymetrix pro-
cedure (Genechip 3′ IVT Express kit, Affymetrix), and
GeneChip Human Genome U133 Plus2.0 arrays were
hybridized overnight with 10 μg cRNA. The slides were
washed and stained using a EukGE-WS2v5 fluidics
protocol on a GeneChip fluidics Station 450, before be-
ing scanned on a GeneChip Scanner 3000 (Affymetrix).
The .CEL files corresponding to this experiment are
available [GEO:GSE15615 and GSE73764].
Immunohistochemistry experiments
GADD45B and PDE4D immunolabeling experiments
were performed using paraffin-embedded synovial sec-
tions obtained in two different cohorts of patients with
early RA. Knee synovial biopsies were obtained by nee-
dle arthroscopy in a first population of 46 patients with
early (disease duration <1 year) ACR/EULAR 2010 clas-
sification criteria-positive RA. These patients were un-
treated at the time of the biopsy (except for use of non
steroidal anti-inflammatory drugs (NSAIDs)). Next, 17 of
them received oral methotrexate (15–20 mg/week), while
the other patients received biological original disease-
modifying anti-rheumatic drugs (DMARDs), alone or in
combination with oral methotrexate (see Additional file 1).
Ultrasound (US)-guided biopsies were obtained in 35
additional patients with early (disease duration <1 year)
untreated ACR/EULAR 2010 classification criteria-
positive RA, prior to initiation of methotrexate therapy
(see Additional file 2). Response to therapy was deter-
mined in both cohorts using EULAR response criteria,
based on DAS28-CRP evaluations at baseline, and
6 months after initiation of therapy.
Knee synovial biopsies were also obtained by needle
arthroscopy from the knee of untreated patients with
psoriatic arthritis (n = 9), and osteoarthritis (n = 12).
After removal of paraffin, sections were incubated in a
sodium citrate buffer (ImmunoDNA Retriever with cit-
rate, BioSB) and heated in a bain-marie for 60 minutes
at 98 °C to retrieve the antigenic sites. Endogenous per-
oxidase was inactivated with Peroxydase Blocking
Reagent (Dako), and nonspecific binding was blocked by
15-minute incubation with 1 × Envision buffer (Dako)
containing 1 % normal human IgG, 5 % bovine serum al-
bumin and 2 % milk. Sections were then incubated over-
night at 4 °C with primary antibody. The following
antibodies were used: GADD45B (rabbit polyclonal, 1/100
dilution, Sigma) and PDE4D (rabbit polyclonal, 1/2,000
dilution, Sigma). After three washes in 1 × Envision buffer,
specifically bound antibodies were labeled with anti-rabbit
Table 1 Patients’ characteristics (high-density transcriptomic
studies)
Patients with early rheumatoid arthritis (n = 21)
Baseline biopsies (number) 21
Follow-up (3 months) biopsies (number) 20
Age at baseline (mean ± SD, years) 51.4 ± 12.8
Gender (female/male, number) 16/5
Anti-citrullinated peptide antibodies status (% positive) 66.7 %
Rheumatoid factor status (% positive) 71.4 %
Disease duration (mean ± SD, years) 0.5 ± 1.1
Disease activity score in 28 joints-CRP in methotrexate
group (n = 9)
Baseline 4.51 ± 1.49
After 3 months 3.84 ± 1.61
After 6 months 3.10 ± 1.54
Good, moderate, poor responders (number at 3 months) 2, 3, 4
Good, moderate, poor responders (number at 6 months) 5, 2, 2
Disease activity score in 28 joints-CRP in
tocilizumab group (n = 12)
Baseline 4.50 ± 1.10
After 3 months 2.35 ± 0.95
After 6 months 2.17 ± 1.14
Good, moderate, poor responders (number at 3 months) 7, 4, 1
Good, moderate, poor responders (number at 6 months) 9, 0, 3
Rheumatoid arthritis patients refractory to TNF blockade
Baseline biopsies, number 12
Follow-up (3 months) biopsies, number 12
Age at baseline (mean ± SD, years) 54.6 ± 16.1
Gender (female/male, number) 9/3
Anti-citrullinated peptide antibodies status (% positive) 50 %
Rheumatoid factor status (% positive) 41.7 %
Patients receiving concomitant methotrexate therapy 100 %
Disease activity score in 28 joints-CRP at baseline 5.80 ± 1.32
Disease activity score in 28 joints-CRP 3 months after
administration of rituximab treatment
4.48 ± 1.28
Disease activity score in 28 joints-CRP disease activity score in 28 joints using
the C-reactive protein level
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Fig. 1 Correlations between clinical disease activity indices and the expression of 51,452 probe sets in 65 synovial biopsy samples from untreated and
treated patients with rheumatoid arthritis (RA). a Distribution of Pearson r correlation coefficients between disease activity score in 28 joints assessed
by C-reactive protein level (DAS28-CRP)/simplified disease activity index (SDAI)/clinical disease activity index (CDAI) and synovial gene expression levels.
b Overlap between probe sets displaying a Pearson r correlation coefficient >0.5 with DAS28-CRP, SDAI and CDAI. c, d Gene set enrichment analyses
and eigenvalues calculations using probe sets displaying a Pearson r correlation coefficient >0.5 with DAS28-CRP indicate that the majority of them are
downregulated by tocilizumab in synovial tissue in RA (c), and a large proportion are induced by TNFα in cultured fibroblast-like synoviocytes (FLS) or
monocytes (d). e Pathway analyses (http://david.abcc.ncifcrf.gov) indicate that transcripts displaying a Pearson r correlation coefficient >0.5 with
DAS28-CRP are significantly enriched in genes associated with T cell activation, inflammatory responses, antigen presentation and lysosomes. Probe
sets belonging to these pathways are downregulated by tocilizumab in RA synovial tissue
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Envision-HRP labeled polymer for 1 hour at room
temperature, and peroxidase activity was revealed by 10-
minute incubation with diaminobenzidine (Dako). As a
final step, sections were washed in tap water and lightly
counterstained with hematoxylin.
Slides were scanned on a Mirax station (Zeiss) and
quantitative analysis of the immunostained sections was
performed using Frida software [11], in accordance with
the digital image analysis process [12]. Six digitized pic-
tures (magnification × 400) were obtained for each slide
by one operator who was blinded to the identity of the
specimens. Each picture included a lining and sublining
region when possible. When the distribution of the
staining was heterogeneous, the pictures were taken in
order to be representative of the whole slide. The surface
staining (S) and the surface of the nuclei (N) were deter-
mined for each image, and the area of staining then was
normalized by calculating the ratio of S to N, and aver-
aging it for each slide. When the quality of the tissue
was insufficient to obtain enough material for quantifica-
tion, the sample was discarded. For GADD45B, this was
the case in 6 out of 46 knee and 9 out of 35 US-guided bi-
opsies. For PDE4D, this was the case in 3 out of 46 knee
and 7 out of 35 US-guided biopsies. Between-group differ-
ences were assessed using the Kruskal–Wallis and Mann–
Whitney tests.
The study was approved by the Ethical Committee of
the Université catholique de Louvain, and informed con-
sent was obtained from all patients.
Results
In order to identify molecular pathways that drive dis-
ease activity in RA synovitis, we calculated the correl-
ation coefficients of clinical disease activity scores
(DAS28-CRP, CDAI, SDAI) with the expression levels of
51,452 individual probe sets in 65 synovial biopsies from
33 different RA patients (collected prospectively before
and after administration of several therapies; see Table 1).
Around 1,000 transcripts displayed a correlation coeffi-
cient (Pearson r) ≥0.5 with disease activity scores
(Fig. 1a). All three disease activity indices generated
strongly overlapping results (Fig. 1b). Gene set enrich-
ment analyses indicated that almost all these transcripts
are downregulated by tocilizumab (anti-IL6R antibody)
in the synovium in early RA, which indicates that they
are, directly or indirectly, IL6-dependent (Fig. 1c). A
large proportion of these transcripts is also TNFα-
dependent, as they are induced by the addition of TNFα
in peripheral blood monocyte and/or FLS cell cultures
(Fig. 1d). Additional pathway analyses indicated that
these transcripts are significantly enriched in T cell acti-
vation, antigen presentation, inflammation and lyso-
some genes, many of which are known tocilizumab
targets in the synovium in RA (Fig. 1e).
Samples used in this first study were obtained from
untreated patients, but also from the same patients
3 months after initiation of methotrexate, tocilizumab or
rituximab therapy. In order to avoid biases associated
with the use of treated samples, we repeated our ana-
lyses, this time only in samples (n = 21) obtained from
untreated patients. Again, all three clinical indices of dis-
ease activity generated strongly overlapping results
(Fig. 2a and b). When looking at transcripts correlating
with individual components of the disease activity scores
(tender joint count, swollen joint count, patient’s global
assessment, physician’s global assessment, CRP), we
found that transcripts correlating with tender joint
count, physician’s global assessment and swollen joint
count displayed the strongest overlap with the global
scores (see Additional file 3). Gene set enrichment ana-
lyses were performed using the transcripts displaying r ≥0.5
with DAS28-CRP. The changes in eigenvalues (i.e., the per-
centage of variation in gene expression explained by the
principal component of the experiment), and the changes
in the amplitude of the effects compared to the initial
analyses showed that these transcripts are much less IL6-
dependent, but still comparably TNFα-dependent (Fig. 2c
and d). Pathway analyses indicated a significant enrichment
in the following functional terms: inflammation, mitosis,
DNA remodeling and lysosomes. Transcripts belonging to
some of these pathways (mitosis, DNA remodeling) are
strongly TNFα-dependent, while transcripts belonging to
the inflammation pathway are both TNFα-dependent and
IL6-dependent (Fig. 2e).
Next, we wondered whether over-expression of
TNFα-induced genes in baseline synovial tissue was also
(See figure on previous page.)
Fig. 2 Correlations between clinical disease activity indices and the expression of 51,452 probe sets in 21 synovial biopsy samples from untreated
patients with early rheumatoid arthritis (RA). a Distribution of Pearson r correlation coefficients between disease activity score in 28 joints assessed by
C-reactive protein level (DAS28-CRP)/simplified disease activity index (SDAI)/clinical disease activity index (CDAI) and synovial gene expression levels.
b Overlap between probe sets displaying a Pearson r correlation coefficient >0.5 with DAS28-CRP, SDAI and CDAI. c, d Gene set enrichment analyses
and eigenvalues calculations using probe sets displaying a Pearson r correlation coefficient >0.5 with DAS28-CRP indicate that a subset of these
transcripts is downregulated by tocilizumab in synovial tissue in RA (c), and a large proportion is induced by TNFα in cultured fibroblast-like
synoviocytes (FLS) or monocytes (d). e Pathway analyses (http://david.abcc.ncifcrf.gov) indicate that transcripts displaying a Pearson r correlation
coefficient >0.5 with DAS28-CRP are significantly enriched in genes associated with inflammation, mitosis, DNA remodeling and lysosomes. The
radar plots indicate how the transcripts belonging to these pathways are influenced by tocilizumab in synovial biopsies, and by TNFα in cultured
monocytes and FLS. INV inverse (a negative effect of tocilizumab appears as positive and suggests a positive effect of IL6)
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associated with overall disease evolution. Six months
after the biopsy, 4 out of 21 patients were non-
responders and 15 were good responders to either
methotrexate or tocilizumab therapy. As shown in
Fig. 3a, transcripts over-expressed in the synovium of
non-responders (see Additional file 4) were significantly
enriched in TNFα-induced genes. In order to confirm
this observation, we performed immunohistochemistry
experiments in two independent cohorts of synovial bi-
opsies, using two TNFα-dependent markers: PDE4D,
which is preferentially induced in TNFα-stimulated fi-
broblasts, and GADD45B, preferentially induced in
TNFα-stimulated monocytes (Fig. 3b). We found that
both molecules are strongly over-expressed in RA com-
pared to osteoarthritis or psoriatic arthritis synovial bi-
opsies (Fig. 4a). In addition, both GADD45B and
PDE4D are significantly over-expressed in baseline syn-
ovial tissue of patients with early RA, who will not re-
spond to methotrexate or original biological DMARDs
given as first line monotherapy or combination therapy.
Out of the 46 RA synovial biopsy samples used in these
immunostaining experiments, 17 were taken prior to
initiation of methotrexate monotherapy. In this sub-
group of samples, baseline over-expression of GADD45B
(but not PDE4D) was significantly associated with poor re-
sponse to therapy. Similarly, baseline over-expression of
GADD45B (but not PDE4D) was associated with poor re-
sponse to methotrexate therapy in an independent set of
US-guided synovial biopsies obtained in patients with
early RA prior to initiation of therapy.
Discussion
We studied correlations between clinical indices of disease
activity and global gene expression levels in RA synovitis.
We found that synovial transcripts correlating with
DAS28-CRP are significantly enriched in TNFα-induced
genes in early RA. In addition, high synovial expression of
TNFα-induced transcripts is associated with poor re-
sponse to therapy in early disease. Immunohistochemistry
experiments on two independent cohorts of patients
confirmed that baseline over-expression of GADD45B, a
molecule induced by TNFα in monocytes in vitro, is asso-
ciated with poor response to therapy in early RA.
Identification of molecular pathways driving disease
activity in RA synovitis is an important step toward a
better understanding of the complex pathogenesis of the
disease. Hence, a careful approach to the data is war-
ranted, in particular when the analytical process is based
on correlative studies. In this perspective, our data illus-
trate nicely how methodological choices can influence
the shape of such correlative results. Thus, our initial
analyses, performed on 65 samples obtained before and
after initiation of methotrexate, tocilizumab or rituximab
therapy, point at a predominant role of IL6-derived
mechanisms in driving disease activity in RA, as almost
all the genes correlating (r ≥0.5) with DAS28-CRP are
downregulated by tocilizumab therapy in RA biopsy
samples. Yet, we recently demonstrated that all three
drugs display very similar molecular effects in RA syno-
vitis, characterized by a downregulation of T cell
activation-associated genes, and a large panel of chemo-
kine and cytokine transcripts [6]. Thus, not only toci-
lizumab, but also rituximab and methotrexate decrease
the expression of IL6-dependent transcripts in RA syno-
vitis. Because these three drugs also downregulate
disease activity, inclusion of post-treatment samples in
our initial analyses increased the odds of finding an
association between IL6-dependent transcripts and
disease activity, and this is what we observed.
We therefore repeated our analyses, excluding samples
from treated patients. In synovial biopsies from patients
with early (untreated) RA, transcripts correlating with
DAS28-CRP (r ≥0.5) are significantly enriched in TNFα-
dependent genes. Some of these genes are also induced
by IL6, but to a lesser extent. The fact that disease activ-
ity score-associated transcripts are more enriched in
TNFα-induced genes in early RA does not mean that
TNFα plays a greater role in disease pathogenesis at this
stage of the disease. Instead, it means that the variables
with the highest weights in the disease activity scores in
patients with active RA (e.g., number of tender and
swollen joints) are more susceptible to direct influence
of TNFα-dependent mechanisms. This could be due to
the fact that TNFα-related mechanisms drive disease ex-
tension, resulting in higher numbers of affected joints.
Alternatively, over-expression of TNFα-induced genes
(See figure on previous page.)
Fig. 3 Higher synovial expression of TNFα-induced transcripts is associated with overall absence of response to therapy in early rheumatoid arthritis
(RA). a Baseline synovial gene expression profiles were compared in poor versus good responders to either tocilizumab or methotrexate therapy at
3 months (4 non-responders versus 9 good responders), and at 6 months (4 non-responders versus 15 good responders). The radar plots indicate how
transcripts over-expressed in poor responders (p <0.05, >1.5-fold change in gene expression) are influenced by tocilizumab in synovial biopsies, and by
TNFα in cultured monocytes and fibroblast-like synoviocytes (FLS). INV inverse (a negative effect of tocilizumab appears as positive and suggests a
positive effect of IL6). b Fold changes in the expression of GADD45B and PDE4D encoding probe sets obtained from HGU133 Plus2.0 transcriptomic
data generated in TNFα-stimulated versus non-stimulated monocytes (n = 3) and FLS (n = 3). Box plots represent minimum, maximum and median
log2 (fold changes) compared to non-stimulated cells. c Typical GADD45B and PDE4D immunostaining pictures (original magnification × 400) obtained
in early RA synovial biopsies, illustrative of marked inter-individual variations in protein expression
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could make affected joints more susceptible to detection
by the clinician. In this perspective, performing similar
analyses with ultrasound rather than clinical scores
would be of interest, in order to evaluate whether ex-
pression of TNFα-dependent transcripts in synovial bi-
opsies correlate with higher gray-scale and power
Doppler signals, hence a higher probability of being de-
tected clinically.
One striking observation is that all three disease activity
indices - DAS28-CRP, SDAI and CDAI - generated highly
concordant results in the correlation analyses with syn-
ovial gene expression data. This is not a surprise consider-
ing that these three indices are calculated based on an
overlapping set of variables (tender joint count, swollen
joint count, CRP, patient’s global assessment, physician’s
global assessment). Comparing the results of the correl-
ation analyses using the global indices, versus each of their
individual components, it appears that the highest overlap
with the global indices is found for the tender joint count
(the variable with the highest weight in all the scores). The
lowest overlap is found for patient’s global assessment,
and CRP. Interestingly, there was also a large overlap
found between the three clinical indices and physician’s
global assessment, although this variable is not included
in the DAS calculation, and has little weight in the SDAI
and CDAI. Although one should not underestimate the
risk of circularity in the reasoning, association of inde-
pendent clinical indices of disease activity with synovial
molecular signatures known to be involved in the patho-
genesis of RA, provides strong extra-clinical support to
the view that these scores adequately and equally capture
information that is truly representative of the disease.
From a clinical point of view, assessment of disease ac-
tivity using synovial transcriptomic data is not the most
valuable information one expects from synovial biopsies,
considering how readily disease activity is evaluated at
the bedside by a trained clinician. Instead, evaluation of
variables associated with less favorable disease outcomes,
and a decreased probability of response to therapy, is
more helpful, not only in daily clinical practice, but also
in the context of patient stratification strategies in clin-
ical trials. In our previous work we demonstrated that
baseline over-expression of TNFα-induced genes in the
synovium from patients with DMARD-resistant RA was
associated with poor response to TNF blockade [7, 8].
Our present gene expression and immunohistochemistry
results obtained from different cohorts of patients indi-
cate that baseline synovial over-expression of TNFα-
induced genes is also associated with poor response to
therapy, in particular methotrexate, in early RA. The fact
that greater synovial expression of TNFα-dependent
molecules is associated with poor therapeutic outcomes
regardless of the drug received by the patient, probably
indicates that this molecular signature is associated with
overall disease severity, rather than with activation of
specific pathways of escape to therapies. Translating this
hypothesis in clinical terms would lead to the speculation
that patients with high synovial expression of TNFα-
induced genes do not necessarily need alternative therapies,
but stronger therapies, a statement that obviously needs to
be verified in further studies (also bearing in mind that esti-
mation of not only drug efficacy, but also toxicity, needs to
be incorporated into personalized treatment algorithms).
In our immunohistochemistry confirmation studies,
we selected GADD45B and PDE4D, because of their in
vitro specific pattern of induction in monocytes versus
FLS, respectively. Both molecules were already subject
to scrutiny in the context of RA. Thus, GADD45B is
mainly expressed in synovial CD68 positive macrophages
in RA, in response to pro-inflammatory cytokines, such
as TNFα [13, 14]. PDE4 isoforms regulate intracellular
cAMP concentrations, and knowledge about their in-
volvement in arthritis mainly originates from clinical
studies on apremilast, a specific PDE4 inhibitor. Apremi-
last is registered for the treatment of psoriasis and psoriatic
arthritis [15]; however, the drug does not have superior effi-
cacy compared to placebo in methotrexate-resistant RA
patients [16]. In our results, baseline over-expression of
both GADD45B and PDE4D is associated with overall poor
response to therapy in a group of untreated patients with
early RA. When we restricted the analyses to methotrexate
therapy, the association remained significant for baseline
GADD45B over-expression in two independent cohorts of
patients with early RA.
(See figure on previous page.)
Fig. 4 Quantification of GADD45B and PDE4D immunostaining in baseline synovial biopsies from patients with early rheumatoid arthritis (RA),
osteoarthritis and psoriatic arthritis. a Needle-arthroscopic synovial biopsies from untreated patients with early RA (n = 46), psoriatic arthritis (n = 9) and
osteoarthritis (n = 12) were stained with polyclonal antibodies directed at GADD45B and PDE4D. Data are represented as the ratio of GADD45B or
PDE4D surface staining to staining of the nuclei. Horizontal bars represent the median values. P values were calculated using Kruskal–Wallis test. b
GADD45B and PDE4D immunostaining in needle-arthroscopic synovial biopsies obtained in patients with early RA prior to initiation of therapy. Patients
are distributed as good, moderate and poor responders to therapy according to European League Against Rheumatism (EULAR) response criteria at
6 months. P values were calculated using Kruskal–Wallis test. c GADD45B and PDE4D immunostaining in needle-arthroscopic (sub-group of population
displayed in a and b) and ultrasound-guided biopsies obtained in patients with early RA prior to initiation of methotrexate therapy.
Patients are distributed as responders or non-responders according to EULAR response criteria at 6 months. P values were calculated
using Mann–Whitney test
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Conclusions
At the present time, stratification of RA patients in clinical
trials is based on parameters (autoantibodies, radiographic
evidence of erosions, acute phase reactants) that are associ-
ated with disease severity, yet are poorly discriminant on an
individual basis. Our data provide a strong rationale for in-
cluding synovial markers of disease severity in the stratifica-
tion panels of clinical trials, in view of their ability to
identify patients with a low overall probability of response
to therapy. The development of minimally invasive tech-
niques (needle arthroscopy and US-guided biopsy) poten-
tially gives access to synovial material from any joint in
ambulatory patients [17]. In addition, a large international
effort is ongoing to standardize pre-analytical and analytical
procedures for synovial biopsy sampling [18]. In this con-
text, our results open perspectives in terms of a new mo-
lecular classification of patients with rheumatoid arthritis,
resulting in a more precise evaluation of disease outcomes
and the need for more aggressive therapies.
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